These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25516014)

  • 1. Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?).
    Athyros VG; Katsiki N; Karagiannis A
    Curr Vasc Pharmacol; 2014; 12(6):867-9. PubMed ID: 25516014
    [No Abstract]   [Full Text] [Related]  

  • 2. B-Natriuretic Peptide Pathway Modulation for the Management of Heart Failure With Reduced Ejection Fraction.
    Renew JR; Cyrille N; Elyahu AY; Ramakrishna H
    J Cardiothorac Vasc Anesth; 2018 Jun; 32(3):1500-1506. PubMed ID: 29373183
    [No Abstract]   [Full Text] [Related]  

  • 3. New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.
    Patel S; Veltri K
    J Pharm Pract; 2017 Oct; 30(5):541-548. PubMed ID: 27194070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?
    Correia LC; Rassi A
    Arq Bras Cardiol; 2016 Jan; 106(1):77-9. PubMed ID: 26815651
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.
    Huet F; Akodad M; Kalmanovitch E; Adda J; Agullo A; Batistella P; Roubille C; Roubille F
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):1-10. PubMed ID: 30345485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
    Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S
    Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508
    [No Abstract]   [Full Text] [Related]  

  • 7. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.
    Rossignol P; Zannad F; Pitt B;
    Int J Cardiol; 2014 Dec; 177(3):731-3. PubMed ID: 25465821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart failure in 2015: Better results from prevention than from additional treatment.
    Køber L
    Nat Rev Cardiol; 2016 Feb; 13(2):75-7. PubMed ID: 26727301
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
    Gori M; Volterrani M; Piepoli M; Senni M
    Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
    King JB; Bress AP; Reese AD; Munger MA
    Pharmacotherapy; 2015 Sep; 35(9):823-37. PubMed ID: 26406774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finding New Echocardiographic Parameters for Reverse Cardiac Remodeling: Isovolumic Contraction Velocity in Heart Failure with Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study.
    Oliveros E; Grapsa J
    J Card Fail; 2024 May; 30(5):666-668. PubMed ID: 38160996
    [No Abstract]   [Full Text] [Related]  

  • 12. First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
    Vardeny O; Tacheny T; Solomon SD
    Clin Pharmacol Ther; 2013 Oct; 94(4):445-8. PubMed ID: 23872864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
    Nguyen E; Weeda ER; White CM
    J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.
    Ramos IC; Versteegh MM; de Boer RA; Koenders JMA; Linssen GCM; Meeder JG; Rutten-van Mölken MPMH
    Value Health; 2017 Dec; 20(10):1260-1269. PubMed ID: 29241885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of angiotensin-neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction.
    Ferrari L; Sada S;
    Intern Emerg Med; 2015 Apr; 10(3):369-71. PubMed ID: 25537439
    [No Abstract]   [Full Text] [Related]  

  • 16. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Kario K
    Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
    Barghash MH; Desai AS
    Clin Pharmacol Ther; 2017 Aug; 102(2):265-268. PubMed ID: 28512738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.